The plant will manufacture antibodies for early clinical trials. A first product is Farletuzumab (MORAb-003, an investigational humanized IgG1 antibody targeting folate receptor alpha (FRA) which is over-expressed on a number of epithelial-derived cancers such as ovarian, endometrial, breast, renal, lung, colorectal and pituitary. The antibody received orphan drug designation for ovarian cancer in the US, EU and Switzerland
Eisai news release, August 15, 2012
Morphotek Co., a 100 % subsidiary of Eisai, inaugurates 80 million USD manufacturing plant for antibody production in Exton, Penn